The slip
PARKINSON RECEIPTno. 1666
18 Oct 2026, 03:34 UTCdopamine neurons, braak
predictionMPV17L2 in dopamine neurons tracks Braak Lewy-body stage
registered2b7b69ca493c0a0d
discovery-0.24 p=0.539 n=9
replication-0.22 p=0.563 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.24, p 0.539)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT97b564f6229694798a4b687b…
follows b19d4d1ff1aa…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 1666: MPV17L2 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.188, n 18), 95% CI -0.69 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.27 (p 0.281, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.120, n 18). could be the mix.
- skeptic
- leave-one-out range -0.41 to -0.22, sign flips 0; without severely affected donors -0.33 (p 0.188, n 18). fragile.
- cell type
- strongest in microglia: -0.65 (p 0.0036, n 18) vs -0.33 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MPV17L2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MPV17L2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.02 p 0.929 (needs p < 9.1e-4)